- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Daratumumab Receives Breakthrough Therapy Designation in Double Refractory Multiple Myeloma from U.S. Food and Drug Administration
Second Janssen oncology compound to receive Breakthrough Therapy Designation
Janssen Submits Marketing Authorisation Application for Simeprevir (TMC435) to the European Medicines Agency for the Treatment of Adult Patients with Chronic Hepatitis C Genotype 1 or Genotype 4
Submission Based on Phase III Data in HCV Patients, Including Patients with Compensated Liver Disease
Janssen Products, LP Modifies Prescribing Information For PROCRIT® (Epoetin alfa) In Chronic Kidney Disease
Revised prescribing information reflects FDA guidance to update labeling for all drugs within ESA class
Richard Petty Teams Up With Janssen Biotech to Launch Show Your Stripes for Prostate Cancer Awareness
Program Builds Prostate Cancer Awareness and Action in Support of America’s Veterans and Adds to Other Janssen Biotech Education Efforts for Men at High Risk, including Making Awareness a Priority (M.A.P.)
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
Designation granted in the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma with a genetic mutation, del17p Ibrutinib is an investigational oral Bruton’s tyrosine kinase inhibitor being studied in several B-cell malignancies